source
- Novo outlines $23B revenue goal, cuts 4,000 jobs and expands Wegovy manufacturing amid investor skepticismNovo held its Capital Markets Day to detail a plan to reach $23 billion in sales by 2035. The company announced another round of layoffs, trimming its workforce by 4,000 people and leaving the head…
- FDA shift sparks renewed pharma and VC focus on osteoporosis drug developmentThe FDA recently altered its regulatory framework for osteoporosis medicines, prompting a wave of renewed interest across the pharmaceutical sector. Earlier, drugs from Eli Lilly, Merck, Novartis…